Abstract
INTRODUCTION While hallmarked by the accumulation of β-amyloid plaques (Aβ) and neurofibrillary tangles (tau) in the brain, Alzheimer’s disease (AD) is a multifactorial disorder that involves additional pathological events, including neuroinflammation, neurodegeneration and synaptic dysfunction. AD-associated biomolecular changes seem to be attenuated in carriers of the functionally advantageous variant of the KLOTHO gene (KL-VSHET). Independently, better cardiorespiratory fitness (CRF) is associated with better health outcomes, both in general and specifically with regard to AD pathology. Here we investigate whether the relationships between CRF (peak oxygen consumption (VO2peak)) and cerebrospinal fluid (CSF) core AD biomarkers and those of neuroinflammation, neurodegeneration, and synaptic dysfunction differ for KL-VSHET compared to non-carriers (KL-VSNC).
METHODS The cohort, enriched for AD risk, consisted of cognitively unimpaired adults (N=136; MeanAGE(SD)=62.5(6.7)) from the Wisconsin Registry for Alzheimer’s Prevention and the Wisconsin Alzheimer’s Disease Research Center. Covariate-adjusted (age, sex, parental AD history, APOE4+ status, and age difference between CSF sampling and exercise test) linear models examined the interaction between VO2peak and KLOTHO genotype on core AD biomarker levels in CSF [phosphorylated tau 181 (pTau181), Aβ42/Aβ40, pTau181/Aβ42]. Analyses were repeated for CSF biomarkers of neurodegeneration [total tau (tTau), α-synuclein (α-syn), neurofilament light polypeptide (NfL)], synaptic dysfunction [neurogranin (Ng)], and neuroinflammation [glial fibrillary acidic protein (GFAP), soluble triggering receptor expressed in myeloid cells (sTREM2), chitinase-3-like protein 1 (YKL-40), interleukin 6 (IL-6), S100 calcium-binding protein B (S100B)].
RESULTS The interaction between VO2peak and KL-VSHET was significant for tTau (P=0.05), pTau181 (P=0.03), Ng (P=0.02), sTREM2 (P=0.03), and YKL-40 (P=0.03), such that lower levels of each biomarker were observed for KL-VSHET who were more fit. No significant KL-VSxVO2peak interactions were observed for Aβ42/Aβ40, pTau181/Aβ42, α-syn, NfL, GFAP, IL-6 or S100B (all Ps>0.09).
CONCLUSIONS We report a synergistic relationship between KL-VSHET and CRF with regard to pTau181, tTau, Ng, sTREM2 and YKL-40, suggesting a protective role for both KL-VSHET and better cardiovascular fitness against unfavorable AD-related changes. Their potentially shared biological mechanisms will require future investigations.
Systematic Review PubMed literature review suggests that both KLOTHO KL-VS genotype and cardiorespiratory fitness (CRF) are associated with pathophysiological processes related to Alzheimer’s Disease (AD). Both KL-VS heterozygotes (KL-VSHET) and those with higher CRF fare better when faced with age-related biomolecular changes of relevance to AD. The present study investigates whether the relationships between CRF and cerebrospinal fluid biomarkers (CSF) of core AD neuropathology, neuroinflammation, neurodegeneration, and synaptic dysfunction differ for KL-VSHET compared to non-carriers.
Interpretation Our findings suggest a synergistic relationship between KL-VSHET and higher CRF against core AD pathology along a range of unfavorable biomolecular changes implicated in this multifactorial disease. This supports the idea that CRF may interact with genetic factors to confer resilience against a multitude of adverse AD-associated processes.
Future Directions Future studies should examine longitudinal changes in CSF biomarkers to determine whether maintaining or improving CRF over time enhances AD resilience in KL-VSHET.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We would like to acknowledge and thank the staff and study participants of the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center and the laboratory technicians at the Clinical Neurochemistry Laboratory at the Mülndal campus, University of Gothenburg, Sweden, without whom this work would not be possible. This work was supported by National Institute on Aging grants R01AG077507 (O.C.O.), R01AG062167 (O.C.O.), R01AG085592 (O.C.O.), R01AG027161 (S.C.J), R01AG021155 (S.C.J.), R01AG054059 (C.E.G.) and P30AG062715 (S.A.); by National Institute of Neurological Disorders and Stroke grant R01NS092918 (D.B.D.); and a Clinical and Translational Science Award (UL1RR025011) to the University of Wisconsin, Madison. Portions of this research were supported by the Veterans Administration, including facilities and resources at the Geriatric Research Education and Clinical Center of the William S. Middleton Memorial Veterans Hospital, Madison, WI; European Research Council (#101053962); the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397); the Swedish Brain Foundation (#FO2017-0243); the Swedish Alzheimer Foundation (#AF-742881); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986; #ALFGBG-71320); and the Knut and Alice Wallenberg Foundation. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Wisconsin School of Medicine and Public Health approved all procedures and all individuals provided a signed informed consent prior to participation in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
